InsidersTradesSigma
Follow the Vincerx Pharma, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vincerx Pharma, Inc. has recorded 25 public disclosures. Market capitalisation: €68k. The latest transaction was reported on 14 August 2023 (Acquisition). Among the most active insiders: Hamdy Ahmed MD. All data is free.
25
Insider Decl.
n/a
Thresholds
€441,837
25 ops.
Buy Volume
n/a
n/a
Sell Volume
64Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 August 2023
Declarations25 total
10,500 shares@ US$0.94934.1% of flowCommon StockSEC:0000950170-23-042406:0
Canonical exit: 9 Nov 2023 (T+90)
16,900 shares@ US$0.94644.1% of flowCommon StockSEC:0000950170-23-041517:0
Canonical exit: 7 Nov 2023 (T+90)
13,036 shares@ US$0.90029.9% of flowCommon StockSEC:0000950170-23-041513:0
Canonical exit: 7 Nov 2023 (T+90)
5,000 shares@ US$0.956.2% of flowCommon StockSEC:0000950170-23-041516:0
Canonical exit: 8 Nov 2023 (T+90)
35,280 shares@ US$0.86568.0% of flowCommon StockSEC:0000899243-22-038529:0
Canonical exit: 14 Mar 2023 (T+90)
7,000 shares@ US$0.837.8% of flowCommon StockSEC:0000899243-22-038528:0
Canonical exit: 14 Mar 2023 (T+90)
28,738 shares@ US$0.884822.1% of flowCommon StockSEC:0000899243-22-038530:0
Canonical exit: 14 Mar 2023 (T+90)
18,400 shares@ US$1.646718.3% of flowCommon StockSEC:0000899243-22-029840:0
Canonical exit: 22 Nov 2022 (T+90)
40,000 shares@ US$1.40780.56% mcap72.5% of flowCommon StockSEC:0000899243-22-024507:0
Canonical exit: 25 Sept 2022 (T+90)
24,200 shares@ US$1.41069.1% of flowCommon StockSEC:0000899243-22-024247:0
Canonical exit: 21 Sept 2022 (T+90)
15,000 shares@ US$1.90830.28% mcap24.3% of flowCommon StockSEC:0000899243-22-022268:0
Canonical exit: 7 Sept 2022 (T+90)
2,402 shares@ US$10.480.23% mcap20.1% of flowCommon StockSEC:0000899243-21-049775:0
Canonical exit: 22 Mar 2022 (T+90)
3,000 shares@ US$10.000.28% mcap41.6% of flowCommon StockSEC:0000899243-21-049777:0
Canonical exit: 23 Mar 2022 (T+90)
1,000 shares@ US$10.230.095% mcap15.0% of flowCommon StockSEC:0000899243-21-049779:0
Canonical exit: 22 Mar 2022 (T+90)
6,450 shares@ US$10.02320.60% mcap20.3% of flowCommon StockSEC:0000899243-21-049763:0
Canonical exit: 22 Mar 2022 (T+90)
2,417 shares@ US$10.33840.23% mcap10.4% of flowCommon StockSEC:0000899243-21-049773:0
Canonical exit: 22 Mar 2022 (T+90)
1,000 shares@ US$11.9610.3% of flowCommon StockSEC:0000899243-21-031927:0
Canonical exit: 2 Nov 2021 (T+90)
799 shares@ US$12.715100.0% of flowCommon StockSEC:0000899243-21-027010:0
Canonical exit: 27 Sept 2021 (T+90)
20,000 shares@ €10.401750.0% of flowCommon StockSEC:0000899243-21-026877:0
Canonical exit: 27 Sept 2021 (T+90)
1,800 shares@ US$12.94328.5% of flowCommon StockSEC:0000899243-21-026819:0
Canonical exit: 28 Sept 2021 (T+90)
500 shares@ US$12.6616.8% of flowCommon StockSEC:0000899243-21-026812:0
Canonical exit: 28 Sept 2021 (T+90)
2,000 shares@ US$12.5852.9% of flowCommon StockSEC:0000899243-21-026813:0
Canonical exit: 27 Sept 2021 (T+90)
6,400 shares@ €10.578150.0% of flowCommon StockSEC:0000899243-21-026816:0
Canonical exit: 27 Sept 2021 (T+90)
7,830 shares@ €10.729429.7% of flowCommon StockSEC:0000899243-21-026820:0
Canonical exit: 27 Sept 2021 (T+90)
7,950 shares@ €10.59639.6% of flowCommon StockSEC:0000899243-21-026817:0
Canonical exit: 27 Sept 2021 (T+90)
25 of 25 declarations
关于 Vincerx Pharma, Inc.
Vincerx Pharma, Inc.（股票代码：VINC）是一家总部位于美国的临床阶段生物制药公司，在美国纳斯达克市场上市。对于欧洲投资者而言，该公司明确属于高风险、高回报的肿瘤生物技术领域，其估值较少受当前收入驱动，更多受管线执行、临床数据和融资能力驱动。该公司起源于 Legacy Vincera Pharma；当前的 Vincerx 名称于 2021 年 1 月启用。其主要行政办公室位于加利福尼亚州圣马特奥，并在莱茵河畔蒙海姆设有一家全资德国子公司，使其拥有虽小但真正国际化的运营足迹。([sec.gov](https://www.sec.gov/Archives/edgar/data/1796129/000119312525065487/d789305d10k.htm)) Vincerx 的商业模式是一家专注于癌症治疗的商业化前生物技术公司。该公司当前的管线在其 SEC 文件中描述为源自一项拜耳许可协议，该协议提供了一项独家、需支付特许权使用费的全球许可，用于开发、制造、商业化、再许可和分销一个临床阶段和后续的小分子项目，以及一个临床前生物偶联平台。其主要资产包括 enitociclib（一种高选择性 CDK9 抑制剂）和 VIP236（一种针对晚期和转移性实体瘤中 alpha-v beta-3 整合素的首创小分子药物偶联物 (SMDC)）。这些项目反映了以精准肿瘤学、新型递送方法和联合治疗潜力为中心的战略。([sec.gov](https://www.sec.gov/Archives/edgar/data/1796129/000119312525065487/d789305d10k.htm)) 从竞争角度来看，Vincerx 在医疗保健领域最拥挤、科学要求最高的领域之一运营。它与大型制药公司、专业肿瘤生物技术公司、学术研究团体和私人药物开发商间接竞争。其差异化取决于其资产能否显示出有意义的治疗窗口、良好的安全性以及足够的临床活性以支持进一步开发。由于该公司仍处于临床阶段，它没有有意义的商业基础来抵消开发风险，这使得执行和资本获取成为投资案例的核心。([sec.gov](https://www.sec.gov/Archives/edgar/data/1796129/000119312525065487/d789305d10k.htm)) 近期公司发展尤为重要。在其 2024 年年度报告中，Vincerx 披露股东已批准并公司于 2025 年 1 月实施了 1 股拆 20 股的反向股票分割。同一份文件显示，截至 2024 年 12 月 31 日，公司拥有约 5.0 million 美元的现金，并持续报告经常性运营亏损和负运营现金流。另外，在 2025 年 4 月，公司宣布计划提交 Form 25 以将其普通股从纳斯达克退市，交易定于 2025 年 4 月 23 日开盘时永久暂停。对于投资者而言，这些是重要信号：故事不再仅仅是临床科学，还涉及上市状态、流动性和资产负债表的可持续性。([sec.gov](https://www.sec.gov/Archives/edgar/data/1796129/000119312525065487/d789305d10k.htm)) 总的来说，Vincerx Pharma 最适合被视为一家投机性的美国肿瘤生物技术公司，拥有两项主要临床资产、有限的财务资源和高度的战略不确定性。其未来取决于它能否在应对纳斯达克艰难的美国公开市场背景下，将科学差异化转化为临床和融资里程碑。([sec.gov](https://www.sec.gov/Archives/edgar/data/1796129/000119312525065487/d789305d10k.htm))
